RZLT Rezolute, Inc.
Price Chart
Executive Summary
Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the $18.9M loss ($-0.27/share) a year ago, driven by lower R&D and G&A expenses. The key catalyst is the expanded CGM analysis from the Phase 3 sunRIZE study presented at PES, showing nominally significant glycemic improvements, though the primary endpoint was previously missed. The stock will move on the FDA's independent evaluation of this data, not the financials.
Actionable Insight
The stock's near-term direction hinges on FDA's response to the submitted sunRIZE datasets, not the financials. Monitor for FDA feedback on whether the CGM data supports a regulatory path forward despite the missed primary endpoint. The upLIFT tumor HI readout in H2 2026 is the next binary catalyst.
Key Facts
- Net loss of $16.2M for Q3 fiscal 2026, improved from $18.9M loss in Q3 fiscal 2025
- EPS of $-0.16 vs $-0.27 year ago; no consensus estimate provided for this quarter
- Cash and investments of $120.3M as of March 31, 2026, down from $167.9M at June 30, 2025
- Expanded CGM analysis from Phase 3 sunRIZE study showed nominally significant reductions in hypoglycemia vs placebo across multiple endpoints
- FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation after March 2026 Type B meeting
- Topline results from upLIFT tumor HI study expected in H2 2026
Financial Impact
No revenue; net loss improved by $2.7M YoY to $16.2M; cash burn of ~$47.6M over 9 months
Risk Factors
- FDA may not accept CGM-based endpoints as sufficient for approval after primary endpoint miss
- Cash runway of $120.3M supports operations but burn rate implies ~2 years of funding without additional capital
- No revenue and pre-commercial stage means stock is entirely driven by clinical/regulatory milestones
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059392 |
| Document: tm2614169d1_8k.htm | 0001104659-26-059392 |
| Document: 0001104659-26-059392-index-headers.html | 0001104659-26-059392 |
| Document: 0001104659-26-059392-index.html | 0001104659-26-059392 |
| Document: 0001104659-26-059392.txt | 0001104659-26-059392 |
| 8-K Data (Synthetic) | 0001104659-26-059392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $3.81 awaiting T+1 | awaiting T+1 | — | $4.00 (+4.99%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $4.51 $4.25 | ▼ −5.76% | ▼ −3.17% | $4.00 (−11.31%) |
|
Jun 2, 2026
11d ago
|
8-K
| $4.00 $4.58 | ▲ +14.50% | ▲ +15.19% | $4.00 (0.00%) |
|
May 12, 2026
4w ago
|
8-K
| $3.33 $3.33 | · 0.00% | ▲ +0.00% | $4.00 (+20.12%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.33 $3.33 | · 0.00% | ▼ −0.00% | $4.00 (−20.12%) |
|
May 1, 2026
6w ago
|
Press Release
| $3.30 $3.30 | · 0.00% | ▲ +0.34% | $4.00 (+21.21%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $3.28 $3.33 | ▼ −1.52% | ▼ −0.51% | $4.00 (−21.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access